Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome
about
Clinical Management of Pancreatic CancerUse of Radiographic Criteria to Predict Outcomes Following Surgery for Pancreatic CancerSerum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancerPotential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy.Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal AdenocarcinomaThe number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyHistopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data.Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.Transport properties of pancreatic cancer describe gemcitabine delivery and responseNeoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?Concomitant major vessel resection in pancreatic adenocarcinoma.Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer.Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomValue of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma.
P2860
Q28084173-7CFBA4B3-CBDA-4AA2-9B04-CA2128A480B7Q28084531-806B9DFA-673E-4ECF-B738-7AE25012DDBFQ33558951-06B579C5-36CA-46D7-B348-AC359C8103C0Q33750803-7ECB6D72-6EF0-4134-914C-99614A6EA4F8Q34701798-E6903981-79C9-4958-AC24-416B28D6B692Q35786058-ACEA3885-EA6E-4146-8C3E-6A250E3AB6EEQ35848380-AF243D58-A908-4129-80C9-A9FCF200F7D8Q35972678-D02EAC23-20D3-4904-A1B4-009744008F33Q36258194-712D7773-18A0-40F4-A729-5A401FAD7A96Q36314356-18D0F5A7-C6DB-4F7F-A4A3-1B075FB31422Q36666622-46C06AF5-0EE3-4876-AE5D-76BB11A649C1Q37277436-F765AF88-3220-4800-8C55-FA942545AF96Q37333036-4E08F23E-5839-4677-B37F-DADDEA6C552AQ37555302-5139B89F-E367-4FF6-BDA7-1F199071B4DCQ37611396-B5E93485-80D7-4F56-95BE-D0FF969F5F26Q37679971-9B4ECB72-1038-4D54-AB58-C32574C1A602Q38074622-72BA6329-B0A1-4C4A-9691-04EF75B4D28FQ38396188-46633361-8DCE-4BE4-BDEC-31C103436FCFQ38566193-E9C98E1D-3A54-49B4-B588-57D1394CE1A6Q38650842-B1A89F61-F217-457D-B2D5-4DFEADDE4496Q38750088-AF196360-F647-4E16-94AD-21D9C45317DCQ38753432-18449254-B9C3-40FB-A21C-C5D59FD17D69Q38998202-19B53ADE-E22D-4490-B4AD-FD76B53BFC21Q39148761-68EBF9CB-F5C9-4BF4-B04A-A2B5AB4B6528Q39342560-7C001AB5-0256-462A-B50B-07F15FBFD106Q39375998-05C6AC27-53FC-4C16-932E-77F0F7D2EA07Q39430849-B8F5AFBD-0817-4F0E-BF8C-174A92D0AB78Q40160341-E3F024BC-6F11-4423-9F76-34ACB1A8A6C3Q40580320-0A36D000-A6EF-4B41-9F9C-94EAF8F8AA49Q41491695-C499F486-5326-4CEB-ADC3-F530780B0FC0Q41867717-3B06D91F-51DD-4BDC-896E-9B1D0F49F131Q44038125-DAB7CCFD-FCB0-4AA0-AC9D-E47251A6BCC3Q45086471-1267EBC7-907E-4BC5-883C-88613FB33BDBQ48165156-7C021F8B-7A45-4C76-875C-9D4903E983A6Q49588315-44AC91A8-6A08-46EA-AAB2-91F0133393F8Q51751748-F21DA8D3-6544-4A02-8765-77978AC2ACFCQ52339747-F52A2982-CDE1-42EA-B4F1-061C2CE7D9B9Q52930315-8EA690FC-78F3-4D8E-85BD-F0090078E253
P2860
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Histologic grading of the exte ...... predictor for patient outcome
@ast
Histologic grading of the exte ...... predictor for patient outcome
@en
type
label
Histologic grading of the exte ...... predictor for patient outcome
@ast
Histologic grading of the exte ...... predictor for patient outcome
@en
prefLabel
Histologic grading of the exte ...... predictor for patient outcome
@ast
Histologic grading of the exte ...... predictor for patient outcome
@en
P2093
P2860
P921
P356
P1433
P1476
Histologic grading of the exte ...... predictor for patient outcome
@en
P2093
Asif Rashid
Christopher Crane
Deyali Chatterjee
Gauri R Varadhachary
Henry F Gomez
Huamin Wang
James L Abbruzzese
Jason B Fleming
Jeffrey E Lee
P2860
P304
P356
10.1002/CNCR.26651
P407
P577
2011-10-25T00:00:00Z